Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

WolverHeme Happy Hour - A podcast by Bernard Marini, Anthony Perissinotti, et al.

In this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!